D-0441-2023 Class II Terminated
FDA drug recall D-0441-2023 was initiated by Teva Pharmaceuticals USA Inc on Feb 22, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit. The recall status is terminated (terminated Dec 6, 2023). Affected quantity: 12,044 Bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 15, 2023
- Initiation Date
- Feb 22, 2023
- Termination Date
- Dec 6, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 12,044 Bottles
Product description
Metformin hydrochloride Extended-Release Tablets, 1000 mg, 60-count bottle, RX only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 00591-2720-60
Reason for recall
CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.
Distribution pattern
CA
Code information
Lot #: 1410946A; Exp. 06/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0441-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026